The use of dostarlimab, a safe and efficient monotherapy in MSI-H rectal cancer patients, an alternative to surgery.

[1]  M. M. Hasan,et al.  Dostarlimab: A breakthrough in the field of oncology , 2022, Annals of medicine and surgery.

[2]  D. Deming.  Total Neoadjuvant Strategies for Locally Advanced Rectal Cancer , 2022, Advances in Oncology.

[3]  Tao Wu,et al.  Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities , 2022, Frontiers in Immunology.

[4]  G. Weiss,et al.  Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial , 2021, Cancer Chemotherapy and Pharmacology.

[5]  R. Tollenaar,et al.  Postoperative complications after colorectal cancer surgery and the association with long-term survival. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  Jeffrey W. Clark,et al.  Radiation Therapy Enhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial , 2021, Nature Cancer.

[7]  D. Fan,et al.  Immunotherapy in colorectal cancer: current achievements and future perspective , 2021, International journal of biological sciences.

[8]  Gong Chen,et al.  Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. , 2021, The oncologist.

[9]  H. Zander,et al.  The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer , 2021, ESMO open.

[10]  L. Moretti,et al.  Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. , 2021, Cancer treatment reviews.

[11]  F. Jamali,et al.  Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma , 2020, Radiation oncology.

[12]  J. Taube,et al.  Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.

[13]  V. Tombolini,et al.  Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis , 2017, BMC Cancer.

[14]  Mary R. Kwaan,et al.  Rectal cancer: An evidence-based update for primary care providers. , 2015, World journal of gastroenterology.

[15]  M. Rengo,et al.  Diffusion-Weighted Magnetic Resonance Application in Response Prediction before, during, and after Neoadjuvant Radiochemotherapy in Primary Rectal Cancer Carcinoma , 2013, BioMed research international.

[16]  OUP accepted manuscript , 2021, British Journal of Surgery.